Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Dickens, Alex M ^a   Yoo, Seung Wan ^a   Chin, Alfred C ^a   Xu, Jiadi ^a   Johnson, Tory P ^a   Trout, Amanda L ^a   Hauser, Kurt F ^b   Haughey, Norman J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CYTOKINE; TRANSACTIVATOR PROTEIN;

AGING; ANIMAL; ASTROCYTE; BRAIN; DEGENERATIVE DISEASE; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; VIROLOGY;

AGING; ANIMALS; ASTROCYTES; BRAIN; CERAMIDES; CYTOKINES; MICE; NEURODEGENERATIVE DISEASES; PHENOTYPE; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 85045956908     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07570-5     Document Type: Article

References (91)

1. Heaton, R. et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. Neurology 75, 2087–2096 (2010)
2. Heaton, R. et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of NeuroVirology 17, 3–16, doi:10.1007/s13365-010-0006-1 (2011)
3. Cysique, L. A., Maruff, P. & Brew, B. J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre-and post-highly active antiretroviral therapy eras: A combined study of two cohorts Clinical Report. Journal of Neurovirology 10, 350–357 (2004)
4. Tozzi, V. et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. Journal of acquired immune deficiency syndromes 45, 174–182, doi:10.1097/QAI.0b013e318042e1ee (2007)
5. Simioni, S. et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. Aids 24, 1243–1250 (2010)
6. Kaul, M., Garden, G. A. & Lipton, S. A. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature Genetics 2, 988–994 (2001)
7. Valcour, V. et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206, 275–282, doi:10.1093/infdis/jis326 (2012)
8. Spudich, S. et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. The Journal of infectious diseases 204, 753–760, doi:10.1093/infdis/jir387 (2011)
9. Ragin, A. B. et al. Brain alterations within the first 100 days of HIV infection. Annals of clinical and translational neurology 2, 12–21 (2015)
10. Ragin, A. B. et al. Structural brain alterations can be detected early in HIV infection. Neurology 79, 2328–2334 (2012)
11. Wang, X. et al. Abnormalities in resting-state functional connectivity in early human immunodeficiency virus infection. Brain connectivity 1, 207–217, doi:10.1089/brain.2011.0016 (2011)
12. Chang, L. et al. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antiviral therapy 8, 17–26 (2003)
13. Hestad, K. et al. Regional brain atrophy in HIV‐1 infection: association with specific neuropsychological test performance. Acta Neurologica Scandinavica 88, 112–118 (1993)
14. Jernigan, T. L. et al. Clinical factors related to brain structure in HIV: the CHARTER study. Journal of neurovirology 17, 248–257 (2011)
15. Cohen, R. A. et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. Journal of neurovirology 16, 25–32 (2010)
16. Paul, R., Cohen, R., Navia, B. & Tashima, K. Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1. Neuroscience & Biobehavioral Reviews 26, 353–359 (2002)
17. Paul, R. H. et al. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. Journal of the International Neuropsychological Society 14, 725–733 (2008)
18. Garden, G. A. Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 40, 240–251, doi:10.1002/glia.10155 (2002)
19. Churchill, M. J. et al. Extensive astrocyte infection is prominent in human immunodeficiency virus–associated dementia. Annals of neurology 66, 253–258 (2009)
20. Saito, Y. et al. Overexpression of nef as a marker for restricted HIV‐1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44, 474–474 (1994)
21. Brack-Werner, R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 13, 1–22 (1999)
22. Neumann, M. et al. Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. Journal of virology 69, 2159–2167 (1995)
23. Tornatore, C., Meyers, K., Atwood, W., Conant, K. & Major, E. Temporal patterns of human immunodeficiency virus type 1 transcripts in human fetal astrocytes. Journal of virology 68, 93–102 (1994)
24. Conant, K. et al. In vivo and in vitro infection of the astrocyte by HIV-1. Adv Neuroimmunol 4, 287–289 (1994)
25. Nath, A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. The Journal of infectious diseases 186(Suppl 2), S193–198 (2002)
26. van Marle, G. et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 329, 302–318, doi:10.1016/j.virol.2004.08.024 (2004)
27. Chompre, G. et al. Astrocytic expression of HIV-1 Nef impairs spatial and recognition memory. Neurobiology of disease 49, 128–136, doi:10.1016/j.nbd.2012.08.007 (2013)
28. Sabatier, J. M. et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. Journal of virology 65, 961–967 (1991)
29. Haughey, N. J., Holden, C. P., Nath, A. & Geiger, J. D. Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J Neurochem 73, 1363–1374 (1999)
30. Ensoli, B. et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. Journal of virology 67, 277–287 (1993)
31. Chauhan, A. et al. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem 278, 13512–13519, doi:10.1074/jbc.M209381200 (2003)
32. Fitting, S. et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177, 1397–1410, doi:10.2353/ajpath.2010.090945 (2010)
33. Fitting, S. et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biological psychiatry 73, 443–453, doi:10.1016/j.biopsych.2012.09.026 (2013)
34. Flexner, C. HIV drug development: the next 25 years. Nat Rev Drug Discov 6, 959–966, doi:10.1038/nrd2336 (2007)
35. Duncan, M. J. et al. Effects of chronic expression of the HIV-induced protein, transactivator of transcription, on circadian activity rhythms in mice, with or without morphine. Am J Physiol Regul Integr Comp Physiol 295, R1680–1687, doi:10.1152/ajpregu.90496.2008 (2008)
36. Kim, B. O. et al. Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162, 1693–1707 (2003)
37. Haughey, N. J. et al. Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci 13, 5120–5130 (2008)
38. Mathias, S. et al. Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta. Science 259, 519–522 (1993)
39. Figuera-Losada, M. et al. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties. PLoS One 10, e0124481, doi:10.1371/journal.pone.0124481 (2015)
40. Friis-Møller, N. et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349, 1993–2003, doi:10.1056/NEJMoa030218 (2003)
41. Sulkowski, M. S., Thomas, D. L., Chaisson, R. E. & Moore, R. D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283, 74–80 (2000)
42. Saylor, D. et al. HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nature Reviews. Neurology 12, 234–U220, doi:10.1038/nrneurol.2016.27 (2016)
43. Heaton, R. K. et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clinical Infectious Diseases 60, 473–480 (2015)
44. Kelly, S. G. et al. Early suppressive antiretroviral therapy in HIV infection is associated with measurable changes in the corpus callosum. Journal of neurovirology 20, 514–520 (2014)
45. Li, S. et al. Matrix metalloproteinase levels in early HIV infection and relation to in vivo brain status. Journal of neurovirology 19, 452–460 (2013)
46. Burdo, T. H. et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. Journal of Infectious Diseases 204, 154–163 (2011)
47. Sailasuta, N. et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection (2012)
48. Kore, I. et al. Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. J Acquir Immune Defic Syndr 70, 393–399, doi:10.1097/QAI.0000000000000746 (2015)
49. Dickens, A. M. et al. Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. AIDS 29, 559–569 (2015)
50. Stout, J. C. et al. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. HIV Neurobehavioral Research Center Group. Archives of neurology 55, 161–168 (1998)
51. Becker, J. T. et al. Subcortical brain atrophy persists even in HAART-regulated HIV disease. Brain imaging and behavior 5, 77–85 (2011)
52. Thompson, P. M. et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci USA 102, 15647–15652, doi:10.1073/pnas.0502548102 (2005)
53. Behrman-Lay, A. M. et al. Human immunodeficiency virus has similar effects on brain volumetrics and cognition in males and females. J Neurovirol 22, 93–103, doi:10.1007/s13365-015-0373-8 (2016)
54. Guha, A. et al. Intrinsic network connectivity abnormalities in HIV-infected individuals over age 60. J Neurovirol 22, 80–87, doi:10.1007/s13365-015-0370-y (2016)
55. Ortega, M., Brier, M. R. & Ances, B. M. Effects of HIV and combination antiretroviral therapy on cortico-striatal functional connectivity. AIDS 29, 703–712, doi:10.1097/QAD.0000000000000611 (2015)
56. Campbell, J. H., Hearps, A. C., Martin, G. E., Williams, K. C. & Crowe, S. M. The importance of monocytes and macrophages in HIV pathogenesis, treatment, and cure. AIDS 28, 2175–2187, doi:10.1097/QAD.0000000000000408 (2014)
57. Walsh, J. G. et al. Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology 11, 35, doi:10.1186/1742-4690-11-35 (2014)
58. Schuenke, K. & Gelman, B. B. Human microglial cell isolation from adult autopsy brain: brain pH, regional variation, and infection with human immunodeficiency virus type 1. Journal of neurovirology 9, 346–357 (2003)
59. Brack-Werner, R. et al. Infection of human brain cells by HIV-1: restricted virus production in chronically infected human glial cell lines. Aids 6, 273–285 (1992)
60. Tardieu, M., Héry, C., Peudenier, S., Boespflug, O. & Montagnier, L. Human immunodeficiency virus type 1-infected monocytic cells can destroy human neural cells after cell-to-cell adhesion. Ann Neurol 32, 11–17, doi:10.1002/ana.410320104 (1992)
61. Thompson, K. A., McArthur, J. C. & Wesselingh, S. L. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Annals of neurology 49, 745–752 (2001)
62. Messam, C. A. & Major, E. O. Stages of restricted HIV-1 infection in astrocyte cultures derived from human fetal brain tissue. Journal of neurovirology 6(Suppl 1), S90–94 (2000)
63. Churchill, M. J. et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Annals of neurology 66, 253–258, doi:10.1002/ana.21697 (2009)
64. Kim, H. J., Martemyanov, K. A. & Thayer, S. A. Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. The. Journal of neuroscience: the official journal of the Society for Neuroscience 28, 12604–12613, doi:10.1523/JNEUROSCI.2958-08.2008 (2008)
65. Zhou, B. Y., Liu, Y., Kim, B., Xiao, Y. & He, J. J. Astrocyte activation and dysfunction and neuron death by HIV-1 Tat expression in astrocytes. Mol Cell Neurosci 27, 296–305, doi:10.1016/j.mcn.2004.07.003 (2004)
66. Pu, H. et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Molecular and cellular neurosciences 24, 224–237 (2003)
67. Haughey, N. J. et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55, 257–267, doi:10.1002/ana.10828 (2004)
68. Nath, A. et al. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 70, 1475–1480 (1996)
69. Haughey, N. J., Nath, A., Mattson, M. P., Slevin, J. T. & Geiger, J. D. HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity. J Neurochem 78, 457–467 (2001)
70. Hui, L., Chen, X., Haughey, N. J. & Geiger, J. D. Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN neuro 4 (2012)
71. Carey, A. N., Sypek, E. I., Singh, H. D., Kaufman, M. J. & McLaughlin, J. P. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 229, 48–56, doi:10.1016/j.bbr.2011.12.019 (2012)
72. Carey, A. N. et al. Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog Neuropsychopharmacol Biol Psychiatry 43, 49–54, doi:10.1016/j.pnpbp.2012.12.018 (2013)
73. Bruce-Keller, A. J. et al. Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 56, 1414–1427, doi:10.1002/glia.20708 (2008)
74. Gelbard, H. A. et al. Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: implications for AIDS neuropathogenesis. Dev Neurosci 15, 417–422 (1993)
75. Bal-Price, A. & Brown, G. C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21, 6480–6491 (2001)
76. Flora, G. et al. Proinflammatory synergism of ethanol and HIV-1 Tat protein in brain tissue. Experimental neurology 191, 2–12 (2005)
77. El-Hage, N. et al. Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca(2+)](i), NF-kappaB trafficking and transcription. PloS one 3, e4093, doi:10.1371/journal.pone.0004093 (2008)
78. Hahn, Y. K. et al. beta-Chemokine production by neural and glial progenitor cells is enhanced by HIV-1 Tat: effects on microglial migration. J Neurochem 114, 97–109, doi:10.1111/j.1471-4159.2010.06744.x (2010)
79. Bermel, R. A. & Bakshi, R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 5, 158–170, doi:10.1016/S1474-4422(06)70349-0 (2006)
80. Rudick, R. A. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 14, 54S–64S, doi:10.1177/1051228404266269 (2004)
81. Chen, J. T. et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 66, 1935–1937, doi:10.1212/01.wnl.0000219816.44094.f8 (2006)
82. Ngwainmbi, J. et al. Effects of HIV-1 Tat on enteric neuropathogenesis. The. Journal of neuroscience: the official journal of the Society for Neuroscience 34, 14243–14251, doi:10.1523/JNEUROSCI.2283-14.2014 (2014)
83. Guedia, J. et al. HIV-1 Tat exacerbates lipopolysaccharide-induced cytokine release via TLR4 signaling in the enteric nervous system. Scientific reports 6, 31203, doi:10.1038/srep31203 (2016)
84. Wall, R. et al. Bacterial neuroactive compounds produced by psychobiotics. Advances in experimental medicine and biology 817, 221–239, doi:10.1007/978-1-4939-0897-4_10 (2014)
85. Hahn, Y. K. et al. Effects of chronic HIV-1 Tat exposure in the CNS: heightened vulnerability of males versus females to changes in cell numbers, synaptic integrity, and behavior. Brain structure & function 220, 605–623, doi:10.1007/s00429-013-0676-6 (2015)
86. Carey, A. N. et al. Conditional Tat protein brain expression in the GT-tg bigenic mouse induces cerebral fractional anisotropy abnormalities. Curr HIV Res 13, 3–9 (2015)
87. Chakos, M. H. et al. Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 44, 675–684 (1998)
88. Johnson, T. P. et al. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proceedings of the National Academy of Sciences of the United States of America 110, 13588–13593, doi:10.1073/pnas.1308673110 (2013)
89. Bandaru, V. V. R. et al. A lipid storage–like disorder contributes to cognitive decline in HIV-infected subjects. Neurology 81, 1492–1499 (2013)
90. Mielke, M. M. et al. Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species. Aging Cell 14, 1014–1023, doi:10.1111/acel.12369 (2015)
91. Mielke, M. M. et al. Factors affecting longitudinal trajectories of plasma sphingomyelins: the Baltimore Longitudinal Study of Aging. Aging cell 14, 112–121, doi:10.1111/acel.12275 (2015)